Hopefully Prof. de Souza can get the screening process underway quickly. Does anyone know what criteria they are using for patient selection, other than the broad trial abstract for IONIC-1 i haven't been able to find clinical trial info online?
Papers like the one below have me excited to see if Veyonda can have a positive impact.
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 | Nature Communications
Hopefully Prof. de Souza can get the screening process underway...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |